Formulation and evaluation of dual release system of mucolytics and macrolides for management of upper respiratory tract infection

Abstract

Results and discussion: All the physical parameters were found acceptable for trial batches. Batch selected for further study was containing HPMC K4M in 30% concentration to tablet weight. The floating lag time found was 69 s. For the coat layer, the optimum batch was selected having least disintegration time that contained crospovidone in 45 mg concentration. All the parameters were found to be acceptable in a range in factorial batches. As the concentration of sodium bicarbonate and HPMC K15M were increased, the floating lag time was decreased. As the concentration of HPMC K15M was increased, the % drug release at 6 h was decreased and as the concentration of sodium bicarbonate was increased, the drug release also increased. As the concentration of HPMC K15M was increased, the % drug release at 10 h was decreased and as the concentration of sodium bicarbonate was increased, the drug release also increased, but the effect is less. The amount of HPMC K4M and sodium bicarbonate were found 42.0 mg and 14.97 mg, respectively for an optimized batch of factorial design. The kinetic mechanism of drug release follows the Higuchi model for the optimized batch. The Korsmeyer Peppas plot indicated that the drug release followed non Fickian diffusion. newlineConclusion: The developed dual release core-compressed tablets of Azithromycin and Bromhexine hydrochloride is a novel approach for the treatment of upper respiratory tract infection. newline newline